US Patent

US8148401 — Benzimidazole derivatives

Composition of Matter · Assigned to Pfizer Inc · Expires 2029-04-14 · 3y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel benzimidazole derivatives, useful in treating abnormal cell growth such as cancer in mammals.

USPTO Abstract

The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3A , R 3B , R 4 , R 5 , X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US8148401
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-04-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.